Transdermal delivery of imipramine and doxepin from newly oil-in-water nanoemulsions for an analgesic and anti-allodynic activity: Development, characterization and in vivo evaluation

Colloids and Surfaces B: Biointerfaces

Volumn 103, Issue , 2013, Pages 558-565

  Sandig, A Gimeno ^a   Campmany, A C Calpena ^a   Campos, F Fernández ^a   Villena, M J Martín ^b   Naveros, B Clares ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Analgesic effect; Antiallodynia; Doxepin; Imipramine; Nanoemulsion; Transdermal delivery

Indexed keywords

ANALGESIC EFFECT; ANTIALLODYNIA; DOXEPIN; IMIPRAMINE; NANOEMULSION; TRANSDERMAL DELIVERY;

OLEIC ACID; SKIN; TRANSMISSION ELECTRON MICROSCOPY;

BEHAVIORAL RESEARCH;

DIETHYLENE GLYCOL MONOETHYL ETHER; DOXEPIN; EXCIPIENT; IMIPRAMINE; ISOSTEARYL ISOSTEARATE; LABRASOL; LIMONENE; OLEIC ACID; PLUROL OLEIQUE; PROPILENGLICOL; UNCLASSIFIED DRUG; WATER;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIALLODYNIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHEMICAL COMPOSITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISPERSION; DROPLET SIZE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; EX VIVO STUDY; HUMAN; IN VIVO STUDY; MALE; MORPHOLOGY; NANOEMULSION; NONHUMAN; PH; PHARMACOLOGICAL PARAMETERS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SKIN PERMEABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSDERMAL DRUG ADMINISTRATION; TRANSMISSION ELECTRON MICROSCOPY; VISCOSITY;

ADMINISTRATION, CUTANEOUS; ANALGESICS; ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; DOXEPIN; DRUG DELIVERY SYSTEMS; EMULSIONS; EVALUATION STUDIES AS TOPIC; HUMANS; HYPERALGESIA; IMIPRAMINE; MALE; NANOPARTICLES; OILS; PERMEABILITY; PHASE TRANSITION; RATS; RATS, SPRAGUE-DAWLEY; SKIN ABSORPTION; WATER;

RATTUS;

EID: 84871128061     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.10.061     Document Type: Article

References (34)

1. Mico J.A., Ardid D., Berrocoso E., Eschalier A. Trends Pharmacol. Sci. 2006, 27:348-354.
2. McMahon S.B., Koltzenburg M. Wall and Melzack's Textbook of Pain 2006, Elsevier, Churchill Livingstone, Philadelphia.
3. Sawynok J. Pharm. Res. 2003, 55:1-20.
4. Max M.B., Culnane M., Schafer S.C., Gracely R.H., Walther D.J., Smoller B., Dubner R. Neurology 1987, 37:589-596.
5. Esser M.J., Sawynok J. Eur. J. Pharmacol. 2000, 399:131-139.
6. Sindrup S.H., Jensen T.S. Pain 1999, 83:389-400.
7. Sawynok J., Esser M.J., Reid A.R. J. Psychiatry Neurosci. 2001, 26:21-29.
8. Sudoh Y., Cahoon E.E., Gerner P., Wang G.K. Anesthesiology 2003, 103:49-55.
9. Haderer A., Gerner P., Kao G., Srinivasa V., Wang G.K. Anesth. Analg. 2003, 96:1707-1710.
10. Brown M.B., Martin G.P., Jones S.A., Akomeah F.K. Drug Deliv. 2006, 13:175-187.
11. Benson H.A.E. Curr. Drug Deliv. 2005, 2:23-33.
12. Shakeel F., Ramadan W. Colloid Surf. B: Biointerfaces 2010, 75:356-362.
13. Divsalar A., Saboury A.A., Nabiuni M., Zare Z., Kefayati M.E., Seyedarabi A. Colloid Surf. B: Biointerfaces 2012, 98:80-84.
14. Gupta R.R., Jain S.K., Varshney M. Colloid Surf. B: Biointerfaces 2005, 41:25-32.
15. Council Regulation (EC) No 440/2008, Test Guideline for Skin Absorption: in vitro Method (B.45), J. Eur. Union (2008) 438-443.
16. Netzlaff F., Kostka K.H., Lehr C.M., Schaefer U.F. Eur. J. Pharm. Biopharm. 2006, 63:44-50.
17. Malfara W.R., Bertucci C., Costa M.E., Dreossi S.A., Pires M.L., Cesarino E.J., Crippa J.A., Costa R.H. J. Pharm. Biomed. Anal. 2007, 44:955-962.
18. European Medicine Agency (EMEA), Guideline on Validation of Bioanalytical Methods, Document Reference EMEA/CHMP/EWP/192217/2009, EMEA, London, 2011.
19. Zimmermann M. Pain 1983, 16:109-110.
20. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. Pain 1988, 32:77-88.
21. Matthews J.N.S., Altman D.G., Campbell M.J., Royston P. Br. Med. J. 1990, 300:230-235.
22. Djekic L., Primorac M. Int. J. Pharm. 2008, 352:231-239.
23. Zhao X., Liu J.P., Zhang X., Li Y. Int. J. Pharm. 2006, 327:58-64.
24. Kogan A., Garti N. Adv. Colloid Interface Sci. 2006, 123-126:369-385.
25. Escribano E., Calpena A.C., Queralt J., Obach R., Domenech J. Eur. J. Pharm. Sci. 2003, 19:203-210.
26. Rastogi S.K., Singh J. J. Pharm. Dev. Technol. 2005, 10:97-104.
27. Pennick G., Harrison S., Jones D., Rawlings A.V. Int. J. Cosmet. Sci. 2010, 32:304-312.
28. Delgado-Charro M.B., Iglesias-Vilas G., Blanco-Mendez J., Lopez-Quintela M.A., Marty J.P., Guy R.H. Eur. J. Pharm. Biopharm. 1997, 43:37-42.
29. Okur, Apaydi{dotless}n S., Yavasoglu N.U.K., Yavasoglu A., Karasulu H.Y. Int. J. Pharm. 2011, 416:136-144.
30. Limpert E., Stahel W.A., Abbt M. Bioscience 2001, 51:341-352.
31. Ereshefsky L., Tran-Johnson T., Davis C.M., LeRoy A. Clin. Chem. 1988, 34:863-880.
32. Gerner P., Srinivasa V., Zizza A.M., Zhuang Z.Y., Luo S.H., Zurakowski D., Eappen S., Wang G.K. Anesth. Analg. 2006, 102:283-287.
33. Cevc G. Adv. Drug Deliv. Rev. 2004, 56:675-711.
34. Tian J., Gu Y., Su D., Wu Y., Wang X. Eur. J. Pain 2009, 13:130-137.